Company intelligence / Profile preview

MGI Pharma

Bloomington / Minneapolis area, Minnesota, United Statesmedia.corporate-ir.net ↗

Ownership: Private
Development stage: Other

Overview

MGI Pharma was a commercial-stage oncology and acute care biopharmaceutical company with a portfolio including approved drugs such as palonosetron hydrochloride ("Aloxi"), decitabine ("Dacogen"), and polifeprosan 20 with carmustine implant ("Gliadel Wafer"). The company also had pipeline assets targeting cancer and other indications. It was acquired by Eisai in early 2008 for $3.9 billion.

Therapeutic areas: HematologyNeurologyOncologyImmunology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Collaborated with partners to reach international markets but no specific major partnerships listed in available sources.Acquired Zycos for pipeline expansion.Licensed or co-marketed some drugs.

Beyond the preview

Go deeper on MGI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGI Pharma.

Explore the full profile